Komori
Semiannual Report4569KYORIN Pharmaceutical Co.,Ltd.Pharmaceuticals

Semiannual Report — FY2026 H1

What KYORIN Pharmaceutical Co.,Ltd. reported for the period from 2026-04-01 to 2027-03-31.

How much it says
56Typical
What moved here
30named for the first time
Its own wording
36terms
Which filing this is
35/ 35newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist

During the interim consolidated accounting period, revenue declined year on year and selling, general and administrative expenses decreased as a reaction to the previous period, while the company recognized a loss on the transfer of the generic pharmaceuticals business under the agreement dated 30 September 2026 as an extraordinary loss. As a result, the company reported an interim net loss attributable to owners of the parent of ¥1,566 million. In addition, the filing discloses the execution of an agreement for the succession of the generic pharmaceuticals business (scheduled succession date: 1 April 2027), as well as agreements for the acquisition of exclusive rights and distribution of EB05, DAYBUE STIX and other products.

Komori's summary of this document, not the document's own words.
56Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
Intensity of Change
61
Detailed
Strategic Shift
63
Detailed
Capital Movement
75
Very detailed
Disclosure gaps
15
Almost nothing
Forward Commitments
41
Thin
Risk changes
55
Typical
Financial and capital policy
100
Very detailed
Specificity of Disclosure
60
Detailed
Product portfolio
11
Almost nothing
Technology position
50
Typical
Confidence in strategic bets
R&D spend4百万円Money spent making new things.
Cash left over11百万円Cash from the business, less what went into equipment.
Spent on equipment1百万円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.
KYORIN Pharmaceutical Co.,Ltd. — FY2026 H1 | Komori